期刊
SEMINARS IN RADIATION ONCOLOGY
卷 29, 期 1, 页码 25-32出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semradonc.2018.10.006
关键词
-
资金
- CCSG [P30-CA086862, R01CA182804, R0ICA184051, P01 CA217797-01A1, R01CA169046]
- Gateway for Cancer Research [G-17-1500T32-GM007337, T32CA078586, T32CA148062]
Chemoradiation has remained the standard of care treatment for many of the most aggressive cancers. However, despite effective toxicity to cancer cells, current chemoradiation regimens are limited in efficacy due to significant normal cell toxicity. Thus, efforts have been made to identify agents demonstrating selective toxicity, whereby treatments simultaneously sensitize cancer cells to protect normal cells from chemoradiation. Pharmacological ascorbate (intravenous infusions of vitamin C resulting in plasma ascorbate concentrations >= 20 mM; P-AscH(-)) has demonstrated selective toxicity in a variety of preclinical tumor models and is currently being assessed as an adjuvant to standard-of-care therapies in several early phase clinical trials. This review summarizes the most current preclinical and clinical data available demonstrating the multidimensional role of P-AscH(-) in cancer therapy including: selective toxicity to cancer cells via a hydrogen peroxide (H2O2)-mediated mechanism; action as a sensitizing agent of cancer cells to chemoradiation; a protectant of normal tissues exposed to chemoradiation; and its safety and tolerability in clinical trials. (C) 2018 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据